TRIDENT is an international medical research study which aims to determine the effect of more intensive blood pressure (BP) control to prevent recurrent stroke in patients who have had an intracerebral haemorrhage (ICH) (a stroke caused by ruptured blood vessel in the brain). Acute ICH accounts for at least 10% of the 20 million new strokes in the world each year. ICH survivors are at high risk of recurrent stroke and other serious cardiovascular (CV) events. Numerous studies have proven the benefit of stroke survivors reducing their risk of recurrent stroke through taking BP-lowering medications. However, studies have shown that many ICH survivors are either not receiving any BP-lowering medication or they are receiving inadequate control.
TRIDENT has been designed to resolve persisting clinical uncertainty and provide definitive evidence on the effectiveness of more intensive BP-lowering treatment after ICH to prevent recurrent serious CV events such as stroke, using a simplified combination of BP-lowering medications on top of standard care. The intensive BP-lowering is provided via a ‘’Triple Pill’’ management strategy – this is a single tablet containing three low-dose BP-lowering medications. Using a combination of low-dose medications has become a common practice in many clinical trials as this method has been proven to deliver greater benefits with fewer side effects.
TRIDENT will be conducted in the following locations (click to zoom):
Project status
Participant recruitment for the TRIDENT study began in August 2017.
1500 patients with ICH will be recruited from approximately 70 centres from around the world.
About
TRIDENT is an international medical research study which aims to determine the effect of more intensive blood pressure (BP) control to prevent recurrent stroke in patients who have had an intracerebral haemorrhage (ICH) (a stroke caused by ruptured blood vessel in the brain). Acute ICH accounts for at least 10% of the 20 million new strokes in the world each year. ICH survivors are at high risk of recurrent stroke and other serious cardiovascular (CV) events. Numerous studies have proven the benefit of stroke survivors reducing their risk of recurrent stroke through taking BP-lowering medications. However, studies have shown that many ICH survivors are either not receiving any BP-lowering medication or they are receiving inadequate control.
TRIDENT has been designed to resolve persisting clinical uncertainty and provide definitive evidence on the effectiveness of more intensive BP-lowering treatment after ICH to prevent recurrent serious CV events such as stroke, using a simplified combination of BP-lowering medications on top of standard care. The intensive BP-lowering is provided via a ‘’Triple Pill’’ management strategy – this is a single tablet containing three low-dose BP-lowering medications. Using a combination of low-dose medications has become a common practice in many clinical trials as this method has been proven to deliver greater benefits with fewer side effects.
TRIDENT will be conducted in the following locations (click to zoom):
Project status
Participant recruitment for the TRIDENT study began in August 2017.
1500 patients with ICH will be recruited from approximately 70 centres from around the world.
TRIDENT